Guidance was slightly improved in Oct '24 - look for confirmation.
• Gross Debt to EBITDA has been stable at just over 3x for several quarters. TACHEM won't go back to single A unless it addresses this. Last quarter this fell from 3.7x to 3.5x. We might see 0.1-0.2x improvement but still too high.
• At CER, Core Revenue was moved from Flat to slight decline to Flat to slight increase
• Core Operating Profits from Approx 10% decline to Mid-single-digit % decline
• Takeda has a significant pipeline of launched and soon-to-be launched products.
• Growth Products grew +18.7% CER last quarter - look for further good news. This represented 47% of total revenue.
• Entyvio (Crohn's disease) launched a Pen in the US which helped sales grow +10.7%. Peak sales are estimated at $7.5-9.0bn. Loses exclusivity in 2026 but extended life with new delivery system. Few biosimilars exist so competition is not thought to be a problem.
• Vyvanse loss of exclusivity means that it only represents <6% of sales now.
• Takeda completed its Yen Hybrid refinancing in June 24 and issued $3bn in long-dated US$. No need to issue.
Find more articles and bullets on these widgets:
| Tenor | Rate | Change |
| One-week | 2.912 | -0.023 |
| One-month | 2.867 | +0.004 |
| Three-month | 2.678 | -0.005 |
| Six-month | 2.562 | -0.015 |
| One-year | 2.454 | -0.011 |
Canadian Finance Minister, Dominic LeBlanc, and Foreign Affairs Minister, Melanie Joly, met on Saturday with two key members of US President-elect Donald Trump’s incoming cabinet to discuss strategy to avoid a 25% tariff that Trump has threatened to impose unless Canada takes steps to secure the border.